Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$318.02 USD

318.02
984,748

+0.10 (0.03%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $318.06 +0.04 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

BDX or WST: Which Is the Better Value Stock Right Now?

BDX vs. WST: Which Stock Is the Better Value Option?

Merit Medical (MMSI) Down 0.7% Since Last Earnings Report: Can It Rebound?

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

HSIC or WST: Which Is the Better Value Stock Right Now?

HSIC vs. WST: Which Stock Is the Better Value Option?

MMSI vs. WST: Which Stock Is the Better Value Option?

MMSI vs. WST: Which Stock Is the Better Value Option?

West Pharmaceutical (WST) Q4 Earnings Beat, Order Book Strong

West Pharmaceutical's (WST) fourth-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.

West Pharmaceutical Services (WST) Q4 Earnings and Revenues Beat Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of 27.34% and 8.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Q4 Earnings on Feb 16: WST, SWAV & More

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat macro headwinds. Let's see how WST, SWAV, AMN, ITGR and PACB are likely to fare this time.

Why West Pharmaceutical (WST) Might Surprise This Earnings Season

West Pharmaceutical (WST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for West Pharmaceutical (WST) in Q4 Earnings?

West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and the bottom lines.

Earnings Preview: West Pharmaceutical Services (WST) Q4 Earnings Expected to Decline

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BDX vs. WST: Which Stock Is the Better Value Option?

BDX vs. WST: Which Stock Is the Better Value Option?

McKesson (MCK) Tops Q3 Earnings and Revenue Estimates

McKesson (MCK) delivered earnings and revenue surprises of 8.83% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

West Pharmaceutical (WST) Q3 Earnings Miss, FY22 View Revised

West Pharmaceutical's (WST) third-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.

West Pharmaceutical Services (WST) Misses Q3 Earnings and Revenue Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of -4.25% and 5.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.

McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for West Pharmaceutical (WST) in Q3 Earnings?

West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and bottom lines.

West Pharmaceutical Services (WST) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Here's Why You Should Retain West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

West Pharmaceutical's (WST) Latest Investment to Boost Business

West Pharmaceutical's (WST) minority investment is expected to aid in meeting patients' continuously evolving needs of ease of use and effective methods of medicine delivery.

West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut

West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.

West Pharmaceutical Services (WST) Q2 Earnings and Revenues Surpass Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of 12.79% and 2.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?